The complicated use of dupilumab in the treatment of atypical generalized pemphigus erythematosus: A report of two cases
| Title: | The complicated use of dupilumab in the treatment of atypical generalized pemphigus erythematosus: A report of two cases |
|---|---|
| Authors: | Jie Chen, Siji Chen, Xia Wu, Xiaoyun Jiang, Yongdong Wang, Hao Cheng |
| Source: | Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023) |
| Publisher Information: | Taylor & Francis Group, 2023. |
| Publication Year: | 2023 |
| Collection: | LCC:Immunologic diseases. Allergy LCC:Therapeutics. Pharmacology |
| Subject Terms: | pemphigus, autoimmunity, immunotherapeutics, dupilumab, biologic agents, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950 |
| More Details: | Pemphigus is a rare autoimmune disease and has the potential to be fatal without treatment. Pemphigus erythematosus (PE) is a benign type of pemphigus foliaceus. Glucocorticoids and immunosuppressive agents are primary therapeutic modalities in pemphigus erythematosus, which may lead to considerable side effects. There is a growing need for new pemphigus therapies with fewer adverse effects. Dupilumab is a humanized monoclonal IgG4 antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) and has been applied for atopic dermatitis and asthma. Recently, dupilumab was thought to be beneficial in aggressive refractory pemphigus vulgaris. We report two cases: a 39-year-old male and a 59-year-old woman diagnosed with PE with atypical clinical features. With dupilumab, patients’ skin lesions significantly improved, and suitable maintenance glucocorticosteroid doses were reached. In conclusion, we reported the short-term effectiveness and safety of dupilumab in two cases of atypical generalized PE. As an adjunct, such a biologic agent is expected to be efficacious in pemphigus erythematosus. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2164-5515 2164-554X 21645515 |
| Relation: | https://doaj.org/toc/2164-5515; https://doaj.org/toc/2164-554X |
| DOI: | 10.1080/21645515.2022.2151290 |
| Access URL: | https://doaj.org/article/cb139f7f44e34bec997c981c11f202b9 |
| Accession Number: | edsdoj.b139f7f44e34bec997c981c11f202b9 |
| Database: | Directory of Open Access Journals |
| ISSN: | 21645515 2164554X |
|---|---|
| DOI: | 10.1080/21645515.2022.2151290 |
| Published in: | Human Vaccines & Immunotherapeutics |
| Language: | English |